Resveratrol Cancer Research Results

RES, Resveratrol: Click to Expand ⟱
Features: polyphenol
Found in red grapes and products made with grapes.
Resveratrol is a polyphenol compound found in various plant species, including grapes, berries, and peanuts.
• Anti-inflammatory effects, Antioxidant effects:
- Antiplatelet aggregation for stroke prevention
- BioAvialability use piperine
- some sources may use Japanese knotweed roots (Reynoutria Japonica - root) as source which might contain Emodin (laxative)
-known as Nrf2 activator, both in cancer and normal cells. Which raises controversity of use in ROS↑ therapies. Interestingly there are reports of NRF2↑ and ROS↑ in cancer cells. This raises the question of if it is a chemosensitizer. However other reports indicate NRF2 droping with Res, indicating it maybe a chemosenstizer.
- RES is also considered to be them most effective natural SIRT1↑ -activating compound (STACs).

However, in the presence of certain metals, such as copper or iron, resveratrol can undergo a process called Fenton reaction, which can lead to the generation of reactive oxygen species (ROS). The pro-oxidant effects of resveratrol are often observed at high concentrations, typically above 50-100 μM, and in the presence of certain metals or other pro-oxidant agents. In contrast, the antioxidant effects of resveratrol are typically observed at lower concentrations, typically below 10-20 μM.

Clinical trials have used doses ranging from 150 mg to 5 grams per day. Lower doses (< 1 g/day) are often well-tolerated, but higher doses might be necessary for therapeutic effects and can be associated with side effects.

-Note half-life 1-3 hrs?.
BioAv poor: min 5uM/L required for chemopreventive effects, but 25mg Oral only yeilds 20nM. co-administration of piperine
Pathways:
- usually induce ROS production in cancer cells, while reducing ROS in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓,
- Lowers AntiOxidant defense in Cancer Cells: NRF2(typically increased), TrxR↓**, SOD↓, GSH↓ Catalase↓ HO1↓(wrong direction), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓">ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, CD133↓, CD24↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Resveratrol can act as a pro-oxidant in cancer cells while functioning as an antioxidant in normal cells
2 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and apoptosis follow ROS elevation in cancer cells
3 SIRT1 / AMPK axis ↑ AMPK; context-dependent SIRT1 modulation ↑ SIRT1 / ↑ AMPK Driver Metabolic stress signaling Resveratrol modulates energy-sensing pathways affecting survival and metabolism
4 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ adaptive suppression Secondary Growth and anabolic inhibition Downregulation of growth signaling contributes to cytostasis and apoptosis sensitization
5 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of survival and inflammatory transcription NF-κB inhibition contributes to reduced proliferation and invasion
6 Cell cycle regulation ↑ G1/S or G2/M arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling disruption
7 HIF-1α / VEGF axis ↓ HIF-1α; ↓ VEGF ↔ minimal Secondary Anti-angiogenic pressure Interference with hypoxia-driven adaptation and angiogenesis


Scientific Papers found: Click to Expand⟱
2206- AgNPs,  RES,    ENHANCED EFFICACY OF RESVERATROL-LOADED SILVER NANOPARTICLE IN ATTENUATING SEPSIS-INDUCED ACUTE LIVER INJURY: MODULATION OF INFLAMMATION, OXIDATIVE STRESS, AND SIRT1 ACTIVATION
- in-vivo, Nor, NA
*hepatoP↑, *Inflam↓, *NF-kB↓, *VEGF↓, *SIRT1↑, *ROS↓, *Dose↝, *Catalase↑, *MDA↓, *MPO↓, *NO↓, *ALAT↓, *AST↓, *antiOx↑,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
6027- CGA,  CUR,  EGCG,  QC,  RES  Contribution of Non-Coding RNAs to Anticancer Effects of Dietary Polyphenols: Chlorogenic Acid, Curcumin, Epigallocatechin-3-Gallate, Genistein, Quercetin and Resveratrol
- Review, Nor, NA
*ROS↓, ROS↑,
5791- CRMs,  HCA,  NAD,  Sper,  RES  Caloric Restriction Mimetics in Nutrition and Clinical Trials
- Review, Nor, NA
*Dose↝, *Glycolysis↓,
5780- CRMs,  HCAs,  RES,  Sper,  ASA  Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential
- Review, Var, NA
*OS↑, *AntiAge↑, *cardioP↑, *neuroP↑, AntiCan↑, *TNF-α↓, *Weight↓, *BP↓, *Inflam↓, *Insulin↓, *ROS↓, *AMPK↑, *mTOR↓, *SIRT1↑, CRM↑,
6416- CUR,  QC,  FA,  RES,  EGCG  Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders
- Review, AD, NA
*DRP1/DNM1L↓, *FIS1↓, *MFN2↑, *OPA1↑, *DRP1/DNM1L↓, *FIS1↓, *OPA1↑, *MFN1↑, *MFN2↑, *DRP1/DNM1L↓, *FIS1↓, *MFN1↑, *MFN2↑, *memory↑, *mtDam↓, *DRP1/DNM1L↓, *FIS1↓,
5397- CUR,  SFN,  RES,  EGCG,  Ash  Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential
- Review, Var, NA
CSCs↓,
4881- CUR,  SFN,  RES,  EGCG,  Lyco  An update of Nrf2 activators and inhibitors in cancer prevention/promotion
- Review, Var, NA
*NRF2↑, *antiOx↑,
3862- CUR,  RES,    The metalloproteinase ADAM10: A useful therapeutic target?
- Review, AD, NA
*SIRT1↑, *ADAM10↑,
3748- CUR,  RES,  Hup,  Riv,  Gala  Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease
- Review, AD, NA
*AChE↓, *Inflam↓, *Aβ↓, *cognitive↑, *ROS↓,
128- CUR,  RES,    Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer
- in-vivo, Pca, NA
lipid-P↓, chemoPv↑, GSH↑, SOD↑, GSTs↑, glucose↓,
134- CUR,  RES,  MEL,  SIL,    Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Apoptosis↑, ROS↑, Trx1↓, TumCG↓, eff↓, TXNIP↑,
182- CUR,  RES,  GI,    Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
p38↓, MKP5↑, TNF-α↓, COX2/PTGS2↓, NF-kB↓,
872- CUR,  RES,    New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects
- in-vitro, BC, TUBO - in-vitro, BC, SALTO
TumCP↓, tumCV↓, p62↓, p62↑, TumAuto↑, TumAuto↓, ROS↑, ROS↓, CHOP/DDIT3↑,
1383- CUR,  BBR,  RES,    Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases
- Review, NA, NA
GSK‐3β↝, ROS↑,
16- Cyc,  RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, N-cadherin↓, E-cadherin↑, Snail↓, TumCI↓, TumMeta↓,
685- EGCG,  CUR,  SFN,  RES,  GEN  The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
- Analysis, NA, NA
Bcl-2↓, survivin↓, XIAP↓, EMT↓, Apoptosis↑, Nanog↓, cMyc↓, OCT4↓, Snail↓, Slug↓, Zeb1↓, TCF↓,
7034- GA,  RES,    The Growth Inhibitory Effect of Resveratrol and Gallic Acid on Prostate Cancer Cell Lines through the Alteration of Oxidative Stress Balance: The Interplay between Nrf2, HO-1, and BACH1 Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCG↓, ROS↓, SOD↑, GPx↑, Catalase↑, GSR↑, GSH↑, HO-1↑, NRF2↑,
4664- GEN,  CUR,  RES,  EGCG,  SFN  Targeting cancer stem cells by nutraceuticals for cancer therapy
- Review, Var, NA
CSCs↓, other↝, eff↑, CD44↓, p‑STAT3↓,
166- GEN,  EGCG,  RES,  CUR,    Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer
- in-vivo, Pca, NA
HH↓, Gli1↓,
7249- Gink,  RES,    Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer
- vitro+vivo, NA, NA
VEGF↓, TumCP↓, TumCMig↓, TumCI↓, ChemoSen↑,
1534- LT,  Api,  EGCG,  RES,    Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action
- in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, PC, Bxpc-3
TumCP↓, Apoptosis↑, eff↓, *toxicity↑, Dose?, eff↓, eff↓,
1721- Lyco,  RES,  VitC,    Lycopene, resveratrol, vitamin C and FeSO4 increase damage produced by pro-oxidant carcinogen 4-nitroquinoline-1-oxide in Drosophila melanogaster: Xenobiotic metabolism implications.
- in-vitro, Pca, PC3 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - in-vitro, BC, MCF7 - in-vitro, Liver, HepG2
ROS↑,
6418- MEL,  RES,    Melatonin improves mitochondrial function by preventing mitochondrial fission in cadmium-induced rat proximal tubular cell injury via SIRT1-PGC-1α pathway activation
- in-vivo, AD, NA
*neuroP↑, *DRP1/DNM1L↓, *FIS1↓, *ROS↓, *MMP↑, *SIRT1↑, *PGC-1α↑, *eff↑,
4703- PTS,  RES,    Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review
- NA, Nor, NA
*AntiAge↑, *eff↑, *Inflam↓, *AntiCan↑, *ROS↓, *Catalase↑, *GSR↑, *HO-1↑, *NAD↑, *NQO1↑, *SOD↑, *NRF2↑,
4701- PTS,  RES,    Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene
- Review, Var, NA
CSCs↓, E-cadherin↑, NF-kB↓, EMT↓, GRP78/BiP↓, CD133↓, COX2/PTGS2↓, β-catenin/ZEB1↓, NOTCH↓,
67- QC,  RES,    Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
cJun↑, AR↓,
873- QC,  RES,  CUR,  PI,    Combination Effects of Quercetin, Resveratrol and Curcumin on In Vitro Intestinal Absorption
- in-vitro, Nor, NA
*BioEnh↑,
3080- RES,    Resveratrol: A miraculous natural compound for diseases treatment
- Review, Var, NA
SIRT1↑, ROCK1↓, AMPK↑, *lipid-P↓, Aβ↓, COX2/PTGS2↓, angioG↓, Hif1a↓, VEGF↓,
3073- RES,    Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy
- in-vitro, Nor, NA
*NLRP3↓, *mtDam↓, *p38↑,
3074- RES,    Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer
- Review, BC, NA
NLRP3↓, SIRT1↑,
3075- RES,  Rad,    The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice
- in-vivo, Nor, NA
*SIRT1↑, *radioP↑, *NLRP3↓, *Weight↑, *IL1β↓,
3076- RES,    Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells
- Review, Var, NA
IL6↓, MMPs↓, MMP2↓, MMP9↓, BioAv↓, Half-Life↑, BioAv↑, Dose↝, angioG↓, IL10↓, VEGF↓, NF-kB↓, COX2/PTGS2↓, SIRT1↑, Wnt↓, cMyc↓, STAT3↓, PTEN↑, ROS↑, RadioS↑, Hif1a↓, E-cadherin↓, Vim↓, angioG↓,
3077- RES,    Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways
- in-vitro, Chon, HTB94
MMP2↓, MMP9↓, SOX9↑, MMPs↓, p‑p38↑, p‑JNK↓, NF-kB↓, HO-1↓,
3078- RES,    The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
- Review, Pca, NA
*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,
3079- RES,    Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action
- Review, Var, NA
angioG↓, TumMeta↓, ChemoSen↑, NADPH↑, SIRT1↑, NF-kB↓, NLRP3↓, Dose↝, COX2/PTGS2↓, MMP9↓, PGE2↓, TIMP1↑, TIMP2↑, Sp1/3/4↓, p‑JNK↓, uPAR↓, ROS↓, CXCR4↓, IL6↓, Gli1↓, *ROS↓, *GSTs↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *GSH↑, eff↑, eff↑, eff↑,
3072- RES,    Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
tumCV↓, TumCP↓, TumCMig↓, Apoptosis↑, NLRP3↓, JAK2↓, STAT3↓, IL1β↓, IL18↓, IL6↓, TNF-α↓, Inflam↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
3084- RES,    Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
- in-vitro, BC, MCF7 - in-vitro, BC, T47D
TumCP↓, EZH2↓, p‑ERK↓,
3085- RES,    Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1
- in-vitro, Cerv, NA
TET1↑, Wnt↓, β-catenin/ZEB1↓,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3087- RES,    Resveratrol cytotoxicity is energy-dependent
- Review, Var, NA
OXPHOS↓, eff↝, eff↑,
3088- RES,    Notch signaling mediated repressive effects of resveratrol in inducing caspasedependent apoptosis in MCF-7 breast cancer cells
- in-vitro, BC, MCF7
NOTCH1↓, BAX↑, CDK4↝, Casp3↑, P21↑,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3071- RES,    Resveratrol and Its Anticancer Effects
- Review, Var, NA
chemoPv↑, SIRT1↑, Hif1a↓, VEGF↓, STAT3↓, NF-kB↓, COX2/PTGS2↓, PI3K↓, mTOR↓, NRF2↑, NLRP3↓, H2O2↑, ROS↑, P53↑, PUMA↑, BAX↑,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
3069- RES,    Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway
- in-vitro, Nor, N9
*antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *AMPK↑, *SIRT1↑, *miR-155↓, *NLRP3↓,
3068- RES,    Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulation
- in-vitro, lymphoma, U937
p65↓, SOD2↓, Prx↓, Catalase↓, Trx↓, TNF-α↓, IL8↓, MCP1/CCL2↓, SIRT1↑,

Showing Research Papers: 1 to 50 of 179
Page 1 of 4 ROS&page=2&exSp=open">Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 179

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   ATF3↑, 1,   Catalase↓, 1,   Catalase↑, 1,   Ferroptosis↑, 1,   GPx↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   H2O2↑, 1,   HO-1↓, 1,   HO-1↑, 3,   lipid-P↓, 2,   lipid-P↑, 1,   NAF1↓, 3,   NRF2↓, 1,   NRF2↑, 8,   OXPHOS↓, 1,   OXPHOS↑, 1,   Prx↓, 1,   ROS↓, 4,   ROS↑, 28,   ROS⇅, 2,   ROS↝, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↑, 3,   SOD2↓, 1,   TAC?, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 1,   Trx1↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   ATP↑, 1,   MKP5↑, 1,   MMP↓, 8,   OCR↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 4,   cMyc↓, 7,   CRM↑, 1,   ECAR↓, 1,   FASN↑, 1,   FBI-1↓, 1,   FDG↓, 1,   FGF21↓, 1,   G6PD↓, 1,   glucose↓, 1,   GlucoseCon↓, 6,   glut↓, 1,   GlutMet↓, 1,   GlutMet↑, 1,   Glycolysis↓, 6,   HK2↓, 6,   lactateProd↓, 7,   LDH↓, 1,   NADPH↑, 1,   PDH↑, 2,   PFK↓, 2,   PFK1↓, 2,   PI3K/Akt↓, 1,   PKM2↓, 7,   POLD1↓, 1,   PPP↓, 1,   R5P↝, 1,   SIRT1↓, 1,   SIRT1↑, 12,   SIRT2↓, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

AhR↓, 1,   Akt↓, 15,   p‑Akt↓, 1,   Apoptosis↑, 19,   BAX↓, 1,   BAX↑, 7,   Bcl-2↓, 9,   Bcl-xL↓, 3,   BIM↑, 1,   BMP2↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 1,   Casp9↑, 4,   CK2↓, 3,   Cyt‑c↑, 4,   Diablo↑, 1,   DR4↑, 2,   DR5↑, 2,   FasL↓, 1,   Ferroptosis↑, 1,   GADD34↑, 1,   iNOS↓, 1,   p‑JNK↓, 2,   MAPK↓, 2,   MAPK↑, 2,   Mcl-1↓, 2,   MDM2↓, 1,   necrosis↑, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 5,   p38↓, 1,   p38↑, 1,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 8,   Telomerase↓, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   SOX9↑, 1,   Sp1/3/4↓, 8,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↑, 1,   EZH2↓, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   other↓, 3,   other↑, 1,   other↝, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 2,   CHOP/DDIT3↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 5,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   GRP94↑, 1,   HSP27↓, 1,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   BNIP3↑, 1,   p62↓, 2,   p62↑, 1,   TumAuto↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   BRCA1↑, 1,   p‑CHK1↑, 1,   DNAdam↓, 1,   DNAdam↑, 3,   DNMTs↓, 2,   P53↑, 11,   p53 Wildtype∅, 1,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   RAD51↓, 1,   SIRT6↑, 1,   TP53↑, 1,   γH2AX↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   CDK4↝, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 9,   cycD1/CCND1↑, 1,   cycE/CCNE↑, 1,   P21↓, 1,   P21↑, 5,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   ALDH1A1↓, 4,   Axin2↓, 1,   CD133↓, 6,   CD24↓, 1,   CD44↓, 6,   CSCs↓, 15,   EMT↓, 17,   EP4/PTGER4↑, 1,   ERK↓, 3,   p‑ERK↓, 1,   FGF↑, 1,   FOXO↑, 2,   FOXO4↓, 1,   Gli1↓, 6,   GSK‐3β↑, 2,   GSK‐3β↝, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 3,   HDAC1↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 7,   IGF-1↓, 2,   IGF-1R↓, 1,   mTOR↓, 8,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH⇅, 1,   NOTCH1↓, 1,   NOTCH2↓, 1,   NOTCH2↑, 1,   OCT4↓, 4,   p300↓, 1,   PI3K↓, 8,   p‑PI3K↓, 1,   PTCH1↓, 2,   PTEN↑, 5,   RAS↓, 1,   Shh↓, 3,   Smo↓, 3,   SOX2↓, 3,   Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   STAT5↓, 1,   TCF↓, 2,   TOP1?, 1,   TOP2↓, 1,   TumCG↓, 9,   Wnt↓, 8,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   ACTA2↓, 1,   AntiAg↑, 2,   Ca+2↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   CXCL12↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 9,   FAK↓, 2,   Fibronectin↓, 1,   Fibronectin↑, 1,   GLI2↓, 1,   HLA↑, 1,   ITGB1↓, 1,   Ki-67↓, 4,   MALAT1↓, 3,   MMP13↓, 1,   MMP2↓, 8,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 14,   MMPs↓, 5,   N-cadherin↓, 6,   N-cadherin↑, 1,   PKCδ↑, 1,   Rho↓, 1,   ROCK1↓, 2,   Slug↓, 3,   Smad1↓, 1,   SMAD2↓, 2,   p‑SMAD2↓, 1,   SMAD3↓, 2,   p‑SMAD3↓, 1,   Snail↓, 6,   Snail↑, 1,   SOX4↓, 1,   talin↓, 1,   TET1↑, 2,   TGF-β↓, 3,   TIMP1↑, 2,   TIMP2↑, 2,   TIMP3↑, 1,   TumCI↓, 15,   TumCMig↓, 9,   TumCP↓, 18,   TumMeta↓, 8,   Twist↓, 1,   TXNIP↑, 1,   uPA↓, 1,   uPAR↓, 1,   Vim?, 1,   Vim↓, 4,   Vim↑, 1,   Zeb1↓, 2,   α-SMA↓, 2,   β-catenin/ZEB1↓, 9,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   ATF4↑, 1,   EGFR↓, 4,   HIF-1↓, 1,   Hif1a↓, 12,   Hif1a↑, 1,   PDGFR-BB↓, 1,   TXA2↑, 1,   VEGF↓, 11,   ZBTB10↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↓, 1,   cellSen↑, 1,   COX2/PTGS2↓, 14,   CRP↓, 1,   CXCR2↑, 1,   CXCR4↓, 2,   FOXP3↓, 1,   IL1↓, 1,   IL10↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 6,   IL8↓, 2,   Inflam↓, 3,   JAK↓, 1,   JAK2↓, 1,   Macrophages↓, 1,   MCP1/CCL2↓, 1,   Neut↓, 1,   NF-kB↓, 16,   p‑NF-kB↓, 2,   p65↓, 1,   PD-1↓, 1,   PD-L1↑, 1,   PGE2↓, 1,   PSA↓, 2,   T-Cell↓, 1,   T-Cell↑, 2,   Th1 response↑, 1,   TNF-α↓, 4,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 5,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 4,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 1,   BioEnh?, 1,   ChemoSen↑, 16,   ChemoSen⇅, 1,   Dose?, 1,   Dose↑, 2,   Dose↝, 9,   eff↓, 4,   eff↑, 20,   eff↝, 3,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 3,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 8,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 4,   BMPs↑, 1,   BRCA1↑, 1,   CRP↓, 1,   E6↓, 1,   EGFR↓, 4,   EZH2↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 6,   Ki-67↓, 4,   LDH↓, 1,   PD-L1↑, 1,   PSA↓, 2,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   AntiTum↑, 4,   cardioP↑, 2,   chemoPv↑, 3,   ChemoSideEff↓, 1,   hepatoP↑, 1,   hepatoP↝, 1,   NKG2D↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 371

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

TMAO↓, 4,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 23,   ARE↝, 1,   Catalase↑, 7,   GPx↑, 5,   GSH↑, 9,   GSR↑, 2,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 11,   HO-1⇅, 1,   Keap1↓, 3,   lipid-P↓, 7,   mt-lipid-P↓, 1,   MDA↓, 4,   Mets↝, 1,   MFN1↑, 2,   MFN2↓, 1,   MFN2↑, 4,   MPO↓, 2,   NQO1↑, 3,   Nrf1?, 1,   NRF2↑, 12,   NRF2↝, 1,   OPA1↓, 1,   OPA1↑, 3,   RNS↓, 1,   ROS↓, 31,   ROS↑, 1,   SIRT3↑, 1,   SOD↑, 7,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 3,   DRP1/DNM1L↓, 5,   DRP1/DNM1L↑, 1,   FIS1↓, 6,   FIS1↑, 1,   Insulin↓, 2,   MMP↑, 3,   mtDam↓, 4,   PGC-1α↓, 1,   PGC-1α↑, 7,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Acetyl-CoA↓, 1,   ALAT↓, 2,   AMPK↑, 13,   cMyc↑, 1,   p‑CREB↑, 2,   CRM↑, 2,   ECAR∅, 1,   FAO↑, 1,   FASN↓, 1,   G6PD↑, 1,   glucose↓, 1,   GlutMet↑, 1,   Glycolysis↓, 1,   Glycolysis↝, 2,   HK2↑, 1,   LDHA↑, 2,   LDL↓, 1,   NAD↑, 1,   NADH:NAD↑, 1,   PDK1 / PDPK1↓, 1,   p‑PDK1 / PDPK1↓, 1,   PKM2↑, 2,   PPARγ↑, 2,   SIRT1↑, 24,   SIRT2↑, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↓, 1,   p‑Akt↑, 1,   Apoptosis↓, 3,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c∅, 1,   iNOS↓, 2,   iNOS↑, 1,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1,   Sp1/3/4↓, 3,   Sp1/3/4↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other?, 3,   other↑, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↝, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   p62↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CLOCK↝, 1,   ERK↓, 1,   FOXO↑, 2,   FOXO1↝, 1,   GSK‐3β↓, 4,   GSK‐3β↑, 1,   IGF-1↓, 3,   IGFBP3↑, 1,   IGFR↓, 1,   mTOR↓, 1,   PI3K↑, 2,   PTEN↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 7,   miR-155↓, 1,   miR-29b↑, 1,   MMP3↓, 1,   MMP9↓, 5,   PKA↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   eNOS↑, 1,   Hif1a↓, 1,   NO↓, 2,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 3,   GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 4,   IL1β↓, 4,   IL6↓, 2,   Inflam↓, 20,   NF-kB↓, 8,   NF-kB↑, 1,   p‑NF-kB↓, 1,   p65↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 3,   ADAM10↑, 6,   BDNF↑, 4,   PSD95↑, 1,   tau↓, 3,   p‑tau↓, 6,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 13,   BACE/β-secretase↓, 3,   NLRP3↓, 4,   PP2A↑, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 9,   BioAv↑, 14,   BioAv↝, 2,   BioAv∅, 1,   BioEnh↑, 1,   DDS↑, 2,   Dose↓, 1,   Dose↑, 1,   Dose↝, 7,   eff↑, 7,   Half-Life↓, 2,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 1,   BP↓, 3,   GutMicro↑, 2,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 6,   AntiCan↑, 2,   cardioP↑, 8,   chemoPv↑, 3,   cognitive↑, 9,   hepatoP↑, 5,   memory↑, 8,   motorD↑, 4,   neuroP↑, 23,   OS↑, 2,   radioP↑, 1,   RenoP↑, 2,   toxicity↓, 3,   toxicity↑, 1,   toxicity∅, 1,   Weight↓, 1,   Weight↑, 1,  
Total Targets: 171

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:141  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page